Study of Rapamycin Plus Ketoconazole in Advanced Cancers
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
To determine the maximum tolerated dose, observed toxicities, and dose limiting toxicities,
and antitumor response of rapamycin plus ketoconazole in patients with advanced cancers.